Dr. Buscema is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
603 N Wilmot Rd
Ste 151
Tucson, AZ 85711Phone+1 520-886-0206Fax+1 520-886-0829
Education & Training
- Johns Hopkins UniversityFellowship, Gynecologic Oncology, 1984 - 1986
- Johns Hopkins UniversityResidency, Obstetrics and Gynecology, 1980 - 1984
- Johns Hopkins University School of MedicineClass of 1980
Certifications & Licensure
- AZ State Medical License 2002 - 2025
- MD State Medical License 1980 - 2012
- American Board of Obstetrics and Gynecology Obstetrics & Gynecology
- American Board of Obstetrics and Gynecology Gynecologic Oncology
Awards, Honors, & Recognition
- Top Doctors:Arizona State Castle Connolly, 2013
- Meaningful Use Stage 1 Certification Centers for Medicare & Medicaid Services, 2012
- Fellow (FACS) American College of Surgeons
Clinical Trials
- BKM120 for Patients With PI3K-activated Tumors Start of enrollment: 2013 Mar 29
- A Study of Prexasertib (LY2606368) in Platinum-Resistant or Refractory Recurrent Ovarian Cancer Start of enrollment: 2018 Apr 10
Publications & Presentations
PubMed
- Population pharmacokinetics and exposure-response relationships of dostarlimab in primary advanced or recurrent endometrial cancer in part 1 of RUBY.Mita Kuchimanchi, Trine Lembrecht Jørgensen, Eva Hanze, Thierry André, Angela Jain
British Journal of Clinical Pharmacology. 2025-03-01 - Tumor Treating Fields therapy in platinum-resistant ovarian cancer: Results of the ENGOT-ov50/GOG-3029/INNOVATE-3 pivotal phase 3 randomized study.Ignace Vergote, Larry J Copeland, Toon Van Gorp, Annouschka Laenen, Giovanni Scambia
European Journal of Cancer. 2025-02-17 - Efficacy and safety of dostarlimab in combination with chemotherapy in patients with dMMR/MSI-H primary advanced or recurrent endometrial cancer in a phase 3, randomiz...Matthew A Powell, David Cibula, David M O'Malley, Ingrid Boere, Mark S Shahin
Gynecologic Oncology. 2025-01-01
Press Mentions
- Who’s Who in Arizona Healthcare for 2024December 15th, 2023
Professional Memberships
- Member
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: